JP5064506B2 - Ｃｂ２受容体調節因子としてのピラジン−２−カルボキサミド誘導体 - Google Patents

Ｃｂ２受容体調節因子としてのピラジン−２−カルボキサミド誘導体 Download PDF

Info

Publication number
JP5064506B2
JP5064506B2 JP2009530841A JP2009530841A JP5064506B2 JP 5064506 B2 JP5064506 B2 JP 5064506B2 JP 2009530841 A JP2009530841 A JP 2009530841A JP 2009530841 A JP2009530841 A JP 2009530841A JP 5064506 B2 JP5064506 B2 JP 5064506B2
Authority
JP
Japan
Prior art keywords
pyrazine
carboxylic acid
methyl ester
amino
pyrrolidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009530841A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010505788A (ja
Inventor
ディーツ，ミッシェル
グリュナー，サビーネ
ヘベイゼン，パウル
メイエール・レイナー，シルヴィー・セー
ネッテコフェン，マティアス
プエルマン，ベルント
レーバー，シュテファン
ウルマー，クリストフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39166552&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5064506(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2010505788A publication Critical patent/JP2010505788A/ja
Application granted granted Critical
Publication of JP5064506B2 publication Critical patent/JP5064506B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
JP2009530841A 2006-10-04 2007-09-24 Ｃｂ２受容体調節因子としてのピラジン−２−カルボキサミド誘導体 Expired - Fee Related JP5064506B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06121749.3 2006-10-04
EP06121749 2006-10-04
PCT/EP2007/060090 WO2008040649A2 (en) 2006-10-04 2007-09-24 Pyrazine-2-carboxamide derivatives as cb2 receptor modulators

Publications (2)

Publication Number Publication Date
JP2010505788A JP2010505788A (ja) 2010-02-25
JP5064506B2 true JP5064506B2 (ja) 2012-10-31

Family

ID=39166552

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009530841A Expired - Fee Related JP5064506B2 (ja) 2006-10-04 2007-09-24 Ｃｂ２受容体調節因子としてのピラジン−２−カルボキサミド誘導体

Country Status (18)

Country Link
US (1) US7691863B2 (pt)
EP (1) EP2076499B1 (pt)
JP (1) JP5064506B2 (pt)
KR (1) KR101114704B1 (pt)
CN (1) CN101522644B (pt)
AR (1) AR063101A1 (pt)
AT (1) ATE467622T1 (pt)
AU (1) AU2007304363B2 (pt)
BR (1) BRPI0717822A2 (pt)
CA (1) CA2664621A1 (pt)
CL (1) CL2007002834A1 (pt)
DE (1) DE602007006531D1 (pt)
ES (1) ES2344128T3 (pt)
IL (1) IL197763A0 (pt)
MX (1) MX2009003316A (pt)
PE (1) PE20080855A1 (pt)
TW (1) TW200825065A (pt)
WO (1) WO2008040649A2 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629346B2 (en) * 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
KR101107896B1 (ko) * 2006-10-04 2012-01-25 에프. 호프만-라 로슈 아게 고 밀도 지단백질(ｈｄｌ)-콜레스테롤 상승제로서 3-피리딘카복스아마이드 및 2-피라진카복스아마이드 유도체
US8088920B2 (en) * 2008-03-31 2012-01-03 Hoffmann-La Roche Inc. 3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents
US7897621B2 (en) * 2008-03-31 2011-03-01 Hoffmann-La Roche Inc. 2-trifluoromethylnicotinamide derivatives as HDL-cholesterol raising agents
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
WO2012031817A1 (en) * 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Determination of abca1 protein levels in cells
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
US9321727B2 (en) * 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
US9403808B2 (en) * 2011-10-28 2016-08-02 Hoffmann-La Roche Inc. Pyrazine derivatives
US9303012B2 (en) * 2012-12-07 2016-04-05 Hoffman-La Roche Inc. Pyridine-2-amides useful as CB2 agonists
MX2015007156A (es) * 2012-12-07 2015-10-14 Hoffmann La Roche Piridina-2-amidas utiles como agonistas receptores de canabinoides 2 (cb2).
PE20151060A1 (es) * 2012-12-07 2015-07-25 Hoffmann La Roche Nuevos derivados de pirazina como agonistas del receptor cb2
CN104837831B (zh) * 2012-12-07 2017-10-31 霍夫曼-拉罗奇有限公司 新的吡啶衍生物
WO2015150438A1 (en) * 2014-04-04 2015-10-08 F. Hoffmann-La Roche Ag 5,6-disubstituted pyridine-2-carboxamides as cannabinoid receptor agonists
EP4108659A1 (en) 2016-06-07 2022-12-28 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
AU2018239542C1 (en) 2017-03-23 2021-02-11 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as SHP2 inhibitors
CN109384734B (zh) * 2017-08-14 2023-04-11 上海科胜药物研发有限公司 一种塞尔西帕中间体的制备方法
JP7454512B2 (ja) 2018-06-27 2024-03-22 エフ． ホフマン－ラ ロシュ アーゲー 優先的カンナビノイド２アゴニストとしてのピリジン及びピラジン誘導体
SG11202009103WA (en) * 2018-06-27 2020-10-29 Hoffmann La Roche Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
WO2023082145A1 (en) * 2021-11-11 2023-05-19 4B Technologies (Suzhou) Limited Intermediate compound of quinoxaline and preparation process thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5738778A (en) * 1980-08-18 1982-03-03 Kyowa Gas Chem Ind Co Ltd Novel cyanopyrazine derivative
UY27939A1 (es) * 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
GB0222493D0 (en) * 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
JP4960085B2 (ja) * 2003-03-19 2012-06-27 エクセリクシス， インク． Ｔｉｅ−２モジュレータと使用方法
US20060135523A1 (en) * 2003-06-18 2006-06-22 Astrazeneca Ab 2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator
US7326706B2 (en) 2003-08-15 2008-02-05 Bristol-Myers Squibb Company Pyrazine modulators of cannabinoid receptors
GB0402357D0 (en) 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
MX2007012213A (es) 2005-04-06 2007-12-10 Hoffmann La Roche Derivados de piridin-3-carboxamida como agonistas inversos de canabinoides.
US7629346B2 (en) * 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives

Also Published As

Publication number Publication date
US7691863B2 (en) 2010-04-06
ES2344128T3 (es) 2010-08-18
PE20080855A1 (es) 2008-06-28
CA2664621A1 (en) 2008-04-10
BRPI0717822A2 (pt) 2013-11-12
AU2007304363B2 (en) 2013-01-17
CN101522644B (zh) 2013-04-24
MX2009003316A (es) 2009-04-09
DE602007006531D1 (de) 2010-06-24
AR063101A1 (es) 2008-12-30
KR20090084842A (ko) 2009-08-05
US20080085905A1 (en) 2008-04-10
WO2008040649A3 (en) 2008-05-29
AU2007304363A1 (en) 2008-04-10
WO2008040649A2 (en) 2008-04-10
ATE467622T1 (de) 2010-05-15
CN101522644A (zh) 2009-09-02
EP2076499B1 (en) 2010-05-12
IL197763A0 (en) 2009-12-24
TW200825065A (en) 2008-06-16
CL2007002834A1 (es) 2008-05-16
KR101114704B1 (ko) 2012-03-14
EP2076499A2 (en) 2009-07-08
JP2010505788A (ja) 2010-02-25

Similar Documents

Publication Publication Date Title
JP5064506B2 (ja) Ｃｂ２受容体調節因子としてのピラジン−２−カルボキサミド誘導体
JP5583694B2 (ja) Ｃｂ２受容体を調節するピロリジン化合物
CA2518774C (en) Heterocyclic n-aryl carboxamides as cytokine inhibitors
JP4865702B2 (ja) サイトカイン阻害剤
JP5411927B2 (ja) Ｃｃｒ１アンタゴニストとしてのピラゾール化合物
CA2757412C (en) Isoxazole-pyridine derivatives as gaba modulators
JP5940523B2 (ja) 窒素含有ヘテロアリール化合物
JP5756800B2 (ja) Ｃｂ２受容体を調節するアゼチジン２−カルボキサミド誘導体
RU2449990C2 (ru) Индолы в качестве модуляторов 5-ht6
JP5496918B2 (ja) Ｃｂ２受容体を調節するアミン化合物及びエーテル化合物
EP2900642B1 (en) Substituted sulfonamide compounds
JP2007514690A (ja) ヒスタミンｈ３アンタゴニストとしてのベンズアゼピン誘導体
EP2291359A1 (en) Phenyl or pyridinyl substituted indazoles derivatives
WO2009047359A1 (en) Inhibitors of protein kinases
ES2920359T3 (es) Amidas de pirrolidinas sustituidas II
WO2007114323A1 (ja) アミノピロリジン化合物
EP1497278B1 (en) Heterocyclic amide derivatives as cytokine inhibitors
KR20160142365A (ko) Cb2 작용제로서 유용한 피리딘-2-아미드
JP6127056B2 (ja) スルホンアミド化合物
WO2024032600A1 (zh) 一种杂环衍生物及其组合物和药学上的应用
EP1867646A1 (en) Cytokine inhibitors

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120704

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120731

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120808

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150817

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees